Pfizer Multiple Myeloma Education Grant

Pfizer Multiple Myeloma Education Grant

Due Date: 12/18/2026

The Pfizer Multiple Myeloma Education Grant offers up to US$250,000 per project for independent medical education in the United States. The call focuses on helping healthcare professionals interpret evidence and coordinate care when using BCMA-directed bispecific antibodies in the second line and beyond for relapsed or refractory multiple myeloma.

Proposals can address gaps in how clinicians interpret trial results, prepare community oncology teams to deliver treatment, or coordinate care across disciplines. The applicant organisation is responsible for designing and delivering the programme independently.

Eligibility Criteria

  • Projects must target healthcare professionals in the United States.
  • Eligible applicants include health professions schools, healthcare institutions, professional societies, medical education companies and other organisations focused on healthcare education or improvement.
  • Individuals and independent medical practice groups without an eligible affiliation cannot receive funding.
  • The project lead must be an employee or contractor of the applicant organisation. The lead or an authorised designee may submit the application.
  • The applicant organisation must be able to receive funding directly from Pfizer and have a key role in any joint project.
  • Organisations offering continuing education credit must be accredited.

Funding Details

  • Maximum award: US$250,000 per project, inclusive of direct costs and overhead.
  • Expected number of awards: Two to three.
  • Institutional overhead: Capped at 28% of the total proposed project budget.

Key Dates

  • Application deadline: December 18, 2026.
  • Expected award notification: February 2027.
  • Anticipated project start: March 2027 or later.

Further Information